01666.HK
Tong Ren Tang Technologies Co. Ltd.
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.16
+2.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.7B | 6.5B | 7.3B | 6.8B | 6.0B |
| Cost of Revenue | 7.8B | 4.0B | 4.4B | 3.9B | 3.4B |
| Gross Profit | 4.9B | 2.5B | 2.9B | 2.8B | 2.6B |
| Operating Expenses | |||||
| R&D Expense | 114.9M | 82.8M | 84.8M | 117.6M | 78.4M |
| SG&A Expense | 3.2B | 1.6B | 1.9B | 1.7B | 1.4B |
| General & Admin Expense | 945.2M | 604.7M | 579.6M | 633.9M | 483.3M |
| Selling & Marketing Expense | 1.6B | 999.9M | 1.3B | 1.1B | 907.6M |
| Other Expenses | (56.5M) | (23.9M) | (85.3M) | (100.6M) | (90.6M) |
| Total Operating Expenses | 3.3B | 1.7B | 1.9B | 1.7B | 1.4B |
| Cost and Expenses | 11.1B | 5.7B | 6.3B | 5.7B | 4.8B |
| Operating Income (EBIT) | 1.6B | 802.1M | 985.2M | 1.1B | 1.2B |
| Non-Operating | |||||
| Interest Income | 61.4M | 68.9M | 76.2M | 91.1M | 44.2M |
| Interest Expense | 52.1M | 59.1M | 64.5M | 45.1M | 53.8M |
| Net Interest Income | 9.3M | 9.9M | 11.8M | 46.1M | (9.6M) |
| Other Non-Op Income/Expense | 42.3M | 20.3M | 76.0M | 46.2M | (1.1M) |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.6B | 822.4M | 1.1B | 1.2B | 1.2B |
| Income Tax Expense | 309.3M | 161.8M | 174.3M | 170.1M | 210.4M |
| Bottom Line | |||||
| Net Income | 735.0M | 396.3M | 521.8M | 590.2M | 582.9M |
| Earnings from Cont. Ops | 1.3B | 660.6M | 886.9M | 992.3M | 1.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 735.0M | 396.3M | 521.8M | 590.2M | 582.9M |
| Per Share | |||||
| Basic EPS | HK$0.57 | HK$0.31 | HK$0.41 | HK$0.46 | HK$0.46 |
| Diluted EPS | HK$0.57 | HK$0.31 | HK$0.41 | HK$0.46 | HK$0.46 |
| Revenue Per Share | HK$9.90 | HK$5.06 | HK$5.67 | HK$5.29 | HK$4.68 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Diluted Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Profitability Metrics | |||||
| EBITDA | 2.0B | 1.0B | 1.2B | 1.3B | 1.4B |
| D&A | 446.7M | 199.1M | 186.1M | 186.1M | 179.2M |
| EBIT | 1.6B | 802.1M | 985.2M | 1.1B | 1.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026